As biopharma’s biologics portfolio continues to grow, its increasing complexity presents a number of challenges for biomanufacturers, according to Sanchayita Ghose, PhD, executive director, Downstream ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback